 |
|
|
 |
About Renagel
Renagel provides effective phosphorus control without the concerns of calcium or metal accumulation.
- Kidney Disease Outcomes Quality Initiative (K/DOQI) recommends sevelamer as a first line treatment option for stage 5 CKD patients[1]
- Established safety profile – used in more than 300,000 patients over 6 years[2]
- Renagel contains no calcium or metal and is not systemically absorbed[3]
- Renagel meets K/DOQI[1]recommended targets for controlling serum phosphorus and Ca x P product
- Serum phosphorus[4] 5.1 mg/dL
- Ca x P product 48[4] 5.1 mg/dL
- Added benefit of significant LDL cholesterol reduction (32%)
- Accessible to your patients – covered and supported by a variety of assistance programs
Effective Phosphorus Control with Renagel
- Renagel achieved K/DOQI targets[1] for serum phosphorus and Ca x P product[4]
- Targets were reached following 52 weeks of Renagel therapy consisting of an average daily consumption of approximately three 800-mg tablets per meal[3]
How does Renagel work?
Renagel’s mechanism of action is to bind phosphate in the gastrointestinal tract and prevent phosphate from being absorbed. Chemically, Renagel is a polyamine – a polymer that is loaded with amines. The purpose of the high density of amine groups on the polymer is to provide a large number of positive charges. The positive charges then interact with the very negatively charged phosphate anions, and thus, the phosphate anions are strongly bound to the polymer cations.
Phosphorus control without the concerns of calcium or metal accumulation.
- Renagel contains no calcium or metals[3]
- Renagel is not systemically absorbed[3]
- Estabished safety profile – Renagel used in over 300,000 patients over 6 years[2]
- Calcium-based binders, metal-based binders, and Renagel are all effective at reducing serum phosphorus.
- Renagel is not absorbed, so it provides phosphorus control without the concerns of calcium or metal accumulation.
References
1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis.
2. Data on file Genzyme Corporation.
3. Prescribing information for Renagel.
4. Chertow GM, et al. Kidney Int. 2002;62:245-252
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
- Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
- Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
- Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
- Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.
Please see accompanying full Prescribing Information.
| |
|
|
|
Genzyme Corporate
